Clinuvel Pharmaceuticals Treats Youngest Patient in Study of Genetic Disorder Drug

MT Newswires Live

Jun 13, 2025

Clinuvel Pharmaceuticals (ASX:CUV) successfully administered Scenesse, or afamelanotide, to a nine-year-old patient in Switzerland with severe symptoms of erythropoietic protoporphyria, a type of genetic disorder characterized by a deficiency in the ferrochelatase enzyme, according to a Friday filing with the Australian bourse.

Scenesse is approved for the prevention of phototoxicity, or sensitivity to light after exposure to a chemical substance, in adult patients with erythropoietic protoporphyria, the filing said.

Following a 2024 pharmacokinetic study that identified no safety concerns in all patients, Clinuvel intends to seek a label update approval in Europe later this year to cover adolescents, the filing added.

The company's shares slipped 2% in recent Friday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2543357323"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543357323\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543357323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543357323","market":"fut","top_or_hot":-1,"title":"Clinuvel Pharmaceuticals Treats Youngest Patient in Study of Genetic Disorder Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) successfully administered Scenesse, or afamelanotide, to a nine-year-old patient in Switzerland with severe symptoms of erythropoietic protoporphyria, a type of genetic disorder characterized by a deficiency in the ferrochelatase enzyme, according to a Friday filing with the Australian bourse.</p><p>Scenesse is approved for the prevention of phototoxicity, or sensitivity to light after exposure to a chemical substance, in adult patients with erythropoietic protoporphyria, the filing said.</p><p>Following a 2024 pharmacokinetic study that identified no safety concerns in all patients, Clinuvel intends to seek a label update approval in Europe later this year to cover adolescents, the filing added.</p><p>The company's shares slipped 2% in recent Friday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Pharmaceuticals Treats Youngest Patient in Study of Genetic Disorder Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Pharmaceuticals Treats Youngest Patient in Study of Genetic Disorder Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-13 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) successfully administered Scenesse, or afamelanotide, to a nine-year-old patient in Switzerland with severe symptoms of erythropoietic protoporphyria, a type of genetic disorder characterized by a deficiency in the ferrochelatase enzyme, according to a Friday filing with the Australian bourse.</p><p>Scenesse is approved for the prevention of phototoxicity, or sensitivity to light after exposure to a chemical substance, in adult patients with erythropoietic protoporphyria, the filing said.</p><p>Following a 2024 pharmacokinetic study that identified no safety concerns in all patients, Clinuvel intends to seek a label update approval in Europe later this year to cover adolescents, the filing added.</p><p>The company's shares slipped 2% in recent Friday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2543357323","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543357323","pubTimestamp":1749784465,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clinuvel Pharmaceuticals  successfully administered Scenesse, or afamelanotide, to a nine-year-old patient in Switzerland with severe symptoms of erythropoietic protoporphyria, a type of genetic disorder characterized by a deficiency in the ferrochelatase enzyme, according to a Friday filing with the Australian bourse.Scenesse is approved for the prevention of phototoxicity, or sensitivity to light after exposure to a chemical substance, in adult patients with erythropoietic protoporphyria, the filing said.Following a 2024 pharmacokinetic study that identified no safety concerns in all patients, Clinuvel intends to seek a label update approval in Europe later this year to cover adolescents, the filing added.The company's shares slipped 2% in recent Friday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","CUV.AU":"CLINUVEL PHARMACEUTICALS LTD"},"translate_title":"Clinuvel Pharmaceuticals治疗遗传疾病药物研究中最年轻的患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":0.9},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) successfully administered Scenesse, or afamelanotide, to a nine-year-old patient in Switzerland with severe symptoms of erythropoietic protoporphyria, a type of genetic disorder characterized by a deficiency in the ferrochelatase enzyme, according to a Friday filing with the Australian bourse.Scenesse is approved for the prevention of phototoxicity, or sensitivity to light after exposure to a chemical substance, in adult patients with erythropoietic protoporphyria, the filing said.Following a 2024 pharmacokinetic study that identified no safety concerns in all patients, Clinuvel intends to seek a label update approval in Europe later this year to cover adolescents, the filing added.The company's shares slipped 2% in recent Friday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}